In a nutshell This trial is examining the safety and effectiveness of mosunetuzumab plus polatuzumab vedotin for B-cell non-Hodgkin’s lymphoma (NHL). The main outcomes to be measured will be the complete response rate and the occurrence of side effects after treatment. This study is recruiting in Miami, Florida, New York City, New York, and Duarte,...
Read MoreIn a nutshell This study looked at the changes in the sense of taste of children with cancer and those who received a stem cell transplant. Researchers found that taste changes in these patients were common. Some background Cancer is often treated with powerful drugs or stem cell transplant. These may have strong side effects. In children, it is...
Read MoreIn a nutshell This study investigated the safety and effectiveness of six versus eight doses of rituximab (Rituxan) in R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for patients with aggressive B-cell lymphoma. This study concluded that adding two extra doses of rituximab to R-CHOP had similar outcomes in these...
Read MoreIn a nutshell This study evaluated the long-term outcomes of radioimmunotherapy (RIT) in patients with follicular lymphoma (FL). This study concluded that RIT is a safe and effective long-term treatment option for these patients. Some background FL is the most common type of non-Hodgkin’s lymphoma. The current standard first-line treatment for...
Read More
In a nutshell This phase 3 trial is investigating the safety and effectiveness of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for mantle cell lymphoma (MCL). The main outcomes to be measured will be survival without cancer growing or spreading and side effects of treatment. The details Mantle cell lymphoma (MCL) is an aggressive type of...
Read More
During July and early August of 2018, the Harris Poll in association with the American Society of Clinical Oncologists (ASCO’s) conducted a poll of 4,887 U.S. adults, 1001 of these have or had cancer. This second annual National Cancer Opinion Survey explored a wide range of topics. The findings clearly describe disparities in the care patients with...
Read More
In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...
Read More
In a nutshell This study investigated complications associated with reduced-intensity EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) therapy for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was associated with high rates of drug delivery complications. Some background...
Read More
In a nutshell This study evaluated the outcomes of patients with mantle cell lymphoma (MCL) after front-line (primary) allogeneic stem cell transplantation (alloSCT). This study concluded that front-line alloSCT is effective in these patients. Some background Chemoimmunotherapy containing rituximab (Rituxan) is the typical front-line...
Read More
In a nutshell This study evaluated the safety and effectiveness of the BR (bendamustine, rituximab) regimen as a second-line treatment for patients with follicular lymphoma (FL) who had disease progression (tumor growth or spread) after chemoimmunotherapy. The study concluded that this regimen was effective in these patients. Some background...
Read More
In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...
Read MoreIn a nutshell This study reviewed recent recommendations in the management of patients with diffuse large B cell lymphoma (DLBCL). Some background DLBCL is the most common type of non-Hodgkin lymphoma (NHL). The current standard treatment includes chemotherapy and immunotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin,...
Read More
